#IPRights are written in the Constitution. Upholding that vision, the Bayh-Dole Act empowers inventors to bring their innovations to market– fueling the leadership the founding fathers envisioned for America. Watch this video from Bayh-Dole Coalition to learn more: youtu.be/rKF744_zPlA?si…

Tying US drug rebates to the lowest GDP-adjusted global rates strips America of its biopharma jobs and state budgets. Most Favored Nation pricing ties US drug rebates to the lowest GDP-adjusted price from a 33-country reference basket. We found that MFN pricing applied to

Over the last five years, the U.S. biopharmaceutical industry has invested $85B in research and manufacturing infrastructure, supporting 1,000+ projects and creating good-paying American jobs. PILMA’s latest report shows how our industry positively impacts the U.S. economy.

The true worth of a medicine goes far beyond its upfront cost. When we only focus on list price, we ignore the downstream effects that innovative therapies deliver - from boosting workforce productivity and easing caregiver burdens to generating scientific breakthroughs that

Most Favored Nation (MFN) reference pricing would tie U.S. drug rebates to the lowest global rates, collapsing the very revenue streams that fund basic science, clinical trials, and manufacturing. Our analysis shows that, over the next decade, applying MFN to Medicare Parts B&D

Brain diseases like Alzheimer’s don’t just affect individuals. They also impact a patient’s family members and community. But innovative new medicines are beginning to change the trajectory of these diseases. Hear from Oskar Hansson at Eli Lilly and Company about his commitment to

The Political Race for Fewer Cures: Trump’s MFN Price Controls on Drugs will Harm U.S. Companies and Patients. - WSJ wsj.com/opinion/donald…

Since 2014, the nation’s three largest PBMs have increased the average number of medicines excluded from many commercial health plans by 27% each year – that includes generics and biosimilars intended to drive patient savings. Learn more from a new study: phrma.org/blog/pbms-not-…

#IntellectualProperty is one of the most powerful economic force multipliers, playing a crucial role in driving economic growth. If you're still questioning the importance of #IPRights, take a look at this insightful report from ndp | analytics: ndpanalytics.com/wp-content/upl…

My Wall Street Journal Opinion piece talks about how a most favored nation drug pricing policy would harm individuals with disabilities… wsj.com/opinion/trumps…

Tim Chapman and Marc Wheat of Advancing American Freedom make a strong case: the threat of #MFN could drive up drug costs, delay cures and erode America’s edge in medical innovation. Read more: nationalreview.com/2025/08/a-bett…

China has already surpassed the U.S. in the number of clinical trials and now, harmful biopharma policies like #MFN threaten to further erode American leadership in innovation. WWFH Executive Director Dan Leonard breaks down why MFN is the wrong approach: ibj.com/articles/dan-l…

From rare disease breakthroughs to job creation, Indiana’s life sciences ecosystem proves what’s possible when federal research, universities & industry work together. Policymakers must keep the momentum going. ibj.com/articles/dan-l…

MFN pricing sounds good but it kills innovation. Copying Europe’s low prices means fewer new cures for patients here at home. dcjournal.com/trump-should-n…

Cutting corners on research policy today could mean fewer lifesaving treatments tomorrow. Keeping America ahead in biomedical innovation isn’t just beneficial -- it's essential. More in IBJ News by We Work For Health ED Dan Leonard Dan Leonard: buff.ly/iRMRvJ3

America has ceded ground to China in biotechnology, including drug development. 2025 Senate report: "Falling further behind would signal a global power shift toward China and create an array of new strategic challenges for the U.S. government": biotech.senate.gov/wp-content/upl…

IWC Responds to Recycled Promises from the #PBM Lobby: tinyurl.com/iwcresponse

Mark Merritt says that PBM commitments to self-regulate are hollow promises meant to evade meaningful reform. If you’re wondering why that matters, it’s because Mark used to represent them. 👀

Want lower drug prices? So does Big Pharma. Read more from Stephen J. Ubl, president of PhRMA: wapo.st/48DXk4X

President Donald Trump has called on U.S. industries to put America first, and the biopharmaceutical sector is answering that call. AmericasMedicines.com